Compare GBX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | NVCR |
|---|---|---|
| Founded | 1974 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Railroads | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2015 |
| Metric | GBX | NVCR |
|---|---|---|
| Price | $51.78 | $12.31 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $49.00 | $28.08 |
| AVG Volume (30 Days) | 214.1K | ★ 1.7M |
| Earning Date | 04-06-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 28.02 | 21.79 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,240,200,000.00 | $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $1.64 | $6.74 |
| P/E Ratio | $45.41 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $37.77 | $9.82 |
| 52 Week High | $59.19 | $20.05 |
| Indicator | GBX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 48.97 |
| Support Level | $44.64 | $10.86 |
| Resistance Level | $54.15 | $13.78 |
| Average True Range (ATR) | 1.45 | 0.78 |
| MACD | -0.80 | -0.09 |
| Stochastic Oscillator | 11.56 | 23.94 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.